Intracranial Control With Combination BRAF and MEK Inhibitor Therapy in Patients With Metastatic Melanoma

Purpose/Objectives Combination BRAF (vemurafenib, dabrafenib, or encorafenib) plus MEK (trametinib, cobimetinib, or binimetinib) inhibitor therapy is now widely used in the treatment of metastatic melanoma. However, data for intracranial response to these drugs are limited. We aimed to evaluate the...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Caressa, Wu, Yufan (Fred), Liu, Kevin, Sandhu, Navjot, Blomain, Erik, Binkley, Michael S, Gephart, Melanie H, Chang, Steven D., Li, Gordon H, Reddy, Sunil A, Soltys, Scott G, Pollom, Erqi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cureus 2022
Materias:
Radiation Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788920/
https://www.ncbi.nlm.nih.gov/pubmed/36579260
http://dx.doi.org/10.7759/cureus.31838

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9788920/
https://www.ncbi.nlm.nih.gov/pubmed/36579260
http://dx.doi.org/10.7759/cureus.31838

Ejemplares similares